What happened
United Therapeutics Corp (NASDAQ: UTHR) EVP and General Counsel Paul A. Mahon sold 8,300 shares on 10/15/2026. The filing puts the price at $541.64 to $546.56 per share, for about $4.52 million in total. Mahon also exercised 8,300 stock options the same day at $146.03 each, and the filing says the trades were made under a Rule 10b5-1 trading plan entered into on August 11, 2025.
After the final sale, Mahon held 45,172 shares. The filing says the sales were executed in multiple trades, with weighted average prices that matched the reported range.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares sold | 8,300 shares | SEC Form 4 | |
| Sale price range | from $541.64 to $546.56 per share | SEC Form 4 | |
| Reported total value | about $4.52 million | SEC Form 4 | |
| Shares held after sale | 45,172 shares | SEC Form 4 | |
| Option exercise price | $146.03 | SEC Form 4 |
Read more: United Therapeutics (UTHR) stock analysis and investment case
Why it matters
OptimistFi's case is that United Therapeutics depends on durable Tyvaso-led pulmonary hypertension cash flows to fund the next growth leg before competition or pricing pressure erodes the franchise.
This filing is mixed because it shows a sizeable insider sale, but it is tied to a same-day option exercise and a pre-arranged Rule 10b5-1 plan entered into on August 11, 2025.
The 8,300 shares were about 15.5% of Mahon's pre-trade holding, and Mahon still held 45,172 shares after the final sale. That leaves the report as an ownership update, not a sign of any change in the company's business trend.
The filing also shows 30,940 stock options beneficially owned after the transactions. That matters because it shows Mahon still has a meaningful equity stake and option exposure even after the disposition, which can soften the read-through from a single sale.
The exercise price of $146.03 was far below the sale range, which is consistent with a long-held grant being converted and then sold. The filing gives investors a clean read on the size and mechanics of the transaction, but not a fresh operating metric or a new business milestone.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
Mahon's next Form 4 filing will be the next observable evidence on whether further sales or option-related trades follow this disclosure. A new filing will update his post-trade stake and show whether the pattern continues.
More from OptimistFi
- UTHR stock: the United Therapeutics thesis, its status and the next test to watch
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
- Weekend market prices: US stock indexes, gold and oil now
- Perps news: leveraged stocks, gold, FX and crypto on-chain
- Prop firms that fund crypto and stock perps traders: rules, prices and payouts
Sources
- SEC Form 4 — Mahon exercised 8,300 options and sold the resulting shares under a Rule 10b5-1 plan, leaving him with 45,172 shares after the final sale.
Read the full OptimistFi thesis on United Therapeutics Corp: https://optimistfi.com/stocks/UTHR
See what would break the United Therapeutics Corp thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full United Therapeutics Corp investment case, its status and the next test to watch live on the United Therapeutics Corp thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
